On this page

Maharashtra FDA withdraws Cipla distribution licence cancellation after Bombay HC rebuke

Maharashtra FDA withdrew its cancellation of Cipla Pharma & Life Sciences’ Pune distribution-unit drug sale licence after Bombay High Court criticised the process. The regulator will issue a fresh show-cause notice over packaging, storage, stock-record and recall compliance issues.

What to watch next

  • Any allegations involving temperature excursions, expired stock, recall failures, falsified records or product-quality risk

Likely next moves

Our read of what comes next — analysis, not reported by the source.

  • Maharashtra FDA is likely to issue a fresh show-cause notice with more specific allegations and a defensible hearing process following the High Court criticism.

The source

Source Read the source at NDTV Profit

Published

Also reported by The Hindu BusinessLine, ET Small Business, Outlook Business

First seen

By

Note Information, not investment advice. RetailIntel is not registered with SEBI.